EBViously Presents Novel In-Vitro Data Demonstrating Potent Infection Prevention of its Vaccine Candidate EBV-001
04 déc. 2023 04h00 HE | AKAMPION
Presentation at the World Vaccine Congress West Coast2023EBV-001 is designed for the prevention of Epstein-Barr Virus (EBV)-induced diseases via high titers of potent, neutralizing antibodiesNovel...
Axim-Sapphire_Logo_-04 (1).png
AXIM Biotechnologies Publishes Study Highlighting Neutralizing Antibody Levels of Poor Vaccine Responders with a Third COVID-19 Vaccine Dose
12 juil. 2022 09h00 HE | AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, July 12, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company, announced today their...
VIR_logo_large.jpg
Vir Biotechnology to Participate in the 42nd Annual Cowen Healthcare Conference
02 mars 2022 16h02 HE | Vir Biotechnology, Inc.
SAN FRANCISCO, March 02, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will participate in an infectious disease panel discussion at the 42nd Annual...
Axim-Sapphire_Logo_-04 (1).png
AXIM Biotechnologies Applauds FDA's Recent COVID-19 Test Policies to Support Rapid Neutralizing Antibody Tests
18 nov. 2021 11h15 HE | AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, Nov. 18, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” or “the Company”), an international healthcare solutions company targeting oncological,...
Axim-Sapphire_Logo_-04 (1).png
AXIM Biotechnologies’ Development of Rapid Test for COVID-19 Neutralizing Antibodies is Cited to Demonstrate over 90% Sensitivity and 100% Specificity
09 nov. 2021 09h00 HE | AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting COVID-19...
Axim-Sapphire_Logo_-04 (1).png
AXIM® Biotechnologies Develops Next Generation of its Rapid Neutralizing Antibody Test for COVID-19
12 oct. 2021 09h00 HE | AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological,...
VIR_logo_large.jpg
Vir Biotechnology Announces First Marketing Authorization for its First Commercial Product, Sotrovimab, Granted in Australia
23 août 2021 08h30 HE | Vir Biotechnology, Inc.
SAN FRANCISCO, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the first marketing authorization, granted in Australia, for its first commercial product,...
VIR_logo_large.jpg
GSK and Vir Biotechnology Announce Joint Procurement Agreement with European Commission for COVID-19 Treatment, Sotrovimab
28 juil. 2021 06h20 HE | Vir Biotechnology, Inc.
LONDON and SAN FRANCISCO, July 28, 2021 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced they have signed a Joint Procurement...
Axim-Sapphire_Logo_-04 (1).png
AXIM® Biotechnologies’ Manufacturing Partner Empowered Diagnostics Files for Approval for Use of Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations in Canada and the EU
05 mai 2021 08h12 HE | AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, May 05, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological...
VIR_logo_large.jpg
Vir Biotechnology Announces New Preclinical Research Demonstrating VIR-7831 Maintains Neutralizing Activity Against the SARS-CoV-2 California Variant
05 avr. 2021 08h00 HE | Vir Biotechnology, Inc.
– Data add to growing body of pre-clinical evidence demonstrating that VIR-7831 maintains activity against all known circulating variants of concern – – Plasma from vaccinated individuals and several...